Australian investment company Channel Capital has partnered with a former Mellon chief to form an incubator in New York. The Aussie group has teamed with Des Mac Intyre, former chief executive of
BioLargo, Inc.: BioLargo Strengthens Balance Sheet by Eliminating Debt as its Commercial Activities Expand
WESTMINSTER, CA / ACCESSWIRE / March 2, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it had paid off $650,000 in debt, the bulk of which was scheduled to mature in August of 2021. Other than debt owed by its partially owned subsidiary Clyra Medical, only SBA loans and fixed-price convertible debt remain on BioLargo s balance sheet. Of the SBA loans, management expects all but the $150,000 EIDL 30-year 3.75% APR loan to be forgiven. Of the fixed price convertible debt, $100,000 will convert to equity automatically at the April 20, 2021 maturity date, the $406,000 due in August 2021 may be converted by the investors at a fixed price of $0.14 at any time, and $50,000 is due in two years.
SEOUL (Reuters): South Korea's factory activity expanded at its fastest pace in nearly 11 years in February, a private survey showed on Tuesday (March 2), as the strongest growth in over a decade in production and new orders drove the recovery in the manufacturing-heavy economy.
(1)
- Rise in investments on contract research manufacturing services (CRAMS) by drug-making companies boost lyophilized injectable drugs market
- Prevalence of metabolic disorders drives optimization of the process of lyophilisation of injectables, demand for new drug formulations for chronic disease management spurs demand in North America
ALBANY, N.Y., March 2, 2021 /PRNewswire/ Lyophilization is a crucial process for injectable for achieving a stable drug product and in ensuring an adequate biological activity. The process regulates numerous key drug product quality attributes such as the cake stability during storage and transportation. A majority of biopharmaceutical such as proteins, vaccines, antibodies, enzymes, biologics, peptides, and plasma need to undergo adequate lyophilisation before commercialization. The process is also being used for some diagnostic reagents, especially those used in IVD. Types of packaging used for lyophilized injectable drugs are single-use v
Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand
Gulf FZ LCC ( Cipla Gulf ), subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as Cipla and biopharmaceutical company Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology.
The products are developed and manufactured by Alvotech and will be distributed by Cipla Gulf through Australia and New Zealand distribution networks. These innovative products recorded US$700 Mn in aggregate 2020 sales in Australia.